FRM
ZBIO icon

Fox Run Management’s Zenas BioPharma ZBIO Stock Holding History

Fox Run Management’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,331
Closed -$243K – 1362
2026
Q1 		$243K Buy
+13,331
New +$299K 0.04% 696

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Fox Run Management's ZBIO Position: Q2 2026 in Review

Fox Run Management sold out of Zenas BioPharma (ZBIO) in Q2 2026, closing a stake of 13,331 shares — an estimated $243K sold.

Fox Run Management first reported a position in ZBIO in Q1 2026 and held it in 1 quarter. The position peaked at $243K in Q1 2026. 144 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • Fox Run Management reported no remaining Zenas BioPharma position as of Q2 2026 after selling out during the quarter.
  • Fox Run Management sold 13,331 Zenas BioPharma shares in Q2 2026, an estimated $243K.
  • Fox Run Management first reported a position in Zenas BioPharma in Q1 2026 and held it in 1 quarter.
  • Fox Run Management's Zenas BioPharma position peaked at $243K in Q1 2026.
  • 144 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.